Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study

Authors: David E. Cohn, Michael W. Sill, Joan L. Walker, David M. O’Malley, Christa Nagel, Teresa Rutledge, William H. Bradley, Debra L. Richardson, Katherine Moxley, Carol Aghajanian - Gynecologic Oncology 2017 cited by 78